聆听生命的足音——访广西玉林制药有限责任公司

中医药是中华民族的优秀文化遗产,然而很长一个时期内,西方医学界对中医药的了解非常有限。直到最近20多年,中医药才广泛传出了国门。据爱尔兰时报两次报道称,当中国人正忙着吸纳西方先进的诊断工具时,西方人也在加速研究中医药对一些疾病的处方……     

国务院关于印发国家药品安全“十二五”规划的通知

1.2012年1月20日国务院公布2.国发〔2012〕5号现将《国家药品安全"十二五"规划》印发给你们,请认真贯彻执行。国家药品安全"十二五"规划     

冀中能源集团有限责任公司

冀中能源集团有限责任公司(以下简称冀中能源)是国有特大型独资公司。2009年6月,冀中能源重组华北制药集团,2010年6月,冀中能源组建了河北航空集团和河北航空公司。形成了以煤炭为主体,以制药、航空为两翼,电力、化工、装备制造、现代物流等多产业综合发展的大型现代企业集团,目前下辖峰峰集团、冀中股份公司、华北制药集团、河北     

Three statutory regimes at impasse： ＂Reverse payments＂ in ＂pay-for-delay＂ settlement agreements between brand-name and generic drug companies

Antitrust authorities in both the United States and Europe have expressed deep concern over settlements of antitrust cases in the pharmaceutical sector, settlements involving ＂reverse payments＂ from plaintiffs to defendants, large sums paid by branded pharmaceutical companies to generic competitors in exchange for promises to stay offthe market. Such ＂pay-for-delay＂ settlements have proliferated in the United States since Federal Circuit Courts of Appeals have found them unproblematic despite the Federal Trade Commission＇s persistently strong position that they violate the antitrust laws. These cases arise at the intersection of three statutory regimes seeking to promote innovation, three clusters of doctrine and policy that have interacted only to reach impasse： the Patent Act, the 1984 amendment to the Food, Drug, and Cosmetic Act, and finally the Sherman Anti-Trust Act. Antitrust is a late comer to the fierce competition over patented drugs, competition that permeates the approval process in the Food ＆ Drug Administration [FDA], competition that is restrained by these pay-for-delay settlement agreements. To set the stage, we begin with the Patent Act and its relationship to the FDA approval process. The story of pay-for-delay settlements then proceeds to the settlement agreements and their antitrust implications. We conclude that the best solution in these antitrust cases would be adoption of the FTC＇s approach of presumptive illegality. Together with an amendment proposed to fix the food and drug act, the presumptive illegality of pay-for-delay settlements under the antitrust laws would make the market for pharmaceuticals more price competitive, open weak patents to serious challenge, and as a result save consumers billions of dollars annually without taking from branded drug companies legitimately earned incentives to engage in research and development.     

谁是专利药到期潮的受益者

随着美国专利药到期潮的来临,全球生物医药行业"风起云涌"众所周知,专利是企业抢占市场和保护市场的重要武器,它就像是"矛"和"盾",在企业开拓市场时充当"利枪",在保护企业利益时又筑起坚固"盾牌"。     

基于创新和学生能力培养的制药工艺学综合性实验改革

以苯妥英钠合成为例,介绍一个可行的制药工艺学综合性实验设计。实验涉及合成路线选择、绿色化学、正交设计、原料药精制及波谱解析等多个知识点,具有实验内容的综合性,实验方法的多元性和实验结果的未知性等特点,有利于培养学生的综合实践和创新意识。     

与病毒赛跑的试剂盒

2月2日晚,新华视频进行了一场题为《夜以继日!各地全力组织医疗防控应急物资生产》的直播。直播中,观众跟随记者走进了位于北京经济技术开发区的北京金豪制药股份有限公司生产车间,让大家目睹了可一次供48人次检测的新型冠状病毒检测试剂盒的真容。北京市政协委员张正是北京金豪制药股份有限公司的总经理。     

打通优化营商环境“最后一公里”

营商环境好不好,企业最有发言权。从当年的小作坊到如今的上市公司,重庆华森制药股份有限公司见证了我市营商环境的不断优化,同时也成为受益者。市人大代表、华森制药董事长游洪涛曾是一名骨科医生,担任过四川省泸州医学院(现更名为西南医科大学)副教授、泸州医学院附二院副院长。1997年,他辞职下海,在荣昌区创办了华森制药。     

国际简讯

国际组织UNCTAD呼吁加强南南技术创新领域合作11月4日,联合国贸易暨发展大会(United Nations Conferenceon Tradeand Development,简称UNCTAD)在《创新、技术和南南合作报告》中指出,在全球产业技术迅速发展的背景下,各发展中国家对于分享新技术和新发明等事项已经开展了卓有成效的南南合作,目前应当将目光投向最不发达国家。根据UNCTAD统计,2010年发展中国家之间贸易总额占世界贸易总额的55%,这得益于新技术在发展中国家之间的流转以及发展中国家创新能力的提升,